Stigma Healing Inventory Evaluation
Stigma
De qué trata este estudio
El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.
- Tipo de estudio
- De intervención
- Fase
- No aplica
- Rango de edad
- 8 años - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- No aceptados
- Participantes
- 2980 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
Investigators want to learn more about the way stigma affects children with cancer and their caregivers. They hope to develop an intervention to lessen stigma for children with cancer and their caregivers in settings around the world.
Leer la descripción completa
Primary Objective 1
- Characterize stigma, including assessment of prevalence of different aspects across three domains and risk factors in diverse pediatric cancer populations.
Primary Objective 2
- Develop and adapt an intervention to improve stigma for children with cancer and their caregivers globally.
Primary Objective 3
- Pilot the preliminary efficacy, feasibility, appropriateness, and acceptability of a patient intervention program to reduce stigma for childhood cancer patients and their caregivers.
The investigators anticipate approximately 1,400 patient enrollees and 1,400 caregiver enrollees (2,800 total) for Aim 1 and 90 dyads (180 total) for Aim 3.
Aim 1:
Approximately 80-100 patients and 80-100 caregivers will be enrolled from each participating center, leading to 1,120-1,400 2,240-2,800 enrollees.
The KidsCanShine and the CaregiversCanShine survey tools will be administered two times to participants. The survey will be administered verbally, on an iPad, or via survey link based on a combination of site resources and preferences, as well as patient preference and abilities. After the first timepoint, participants will remain enrolled in the study for six months. Six months (+/- 1 month) after initial enrollment and survey completion, study team members will reach out to patients and their caregivers and ask them to complete the same survey at this second time point. At the conclusion of this second survey, participants will be finished with the study.
Aim 2 does not involve participant interaction. The goal of this Aim is to develop the intervention that will be randomized and delivered to participants during Aim 3.
Aim 3: Investigators will pilot the stigma reduction intervention and test its preliminary efficacy. In this clustered randomized control trial (RCT), investigators will compare 3 sites randomized to the fully developed intervention and 3 sites randomized to education only, delivered via patient referral to the Together platform and provision of Together educational materials. The 6 sites will be determined based on the results of Aim 1 and site interest.
The intervention will include multiple sessions, group and individual, covering various components aligned with our conceptual model and the domains assessed via KidsCanSHINE and CaregiversCanSHINE. Sessions will include beliefs and myths, cancer education, disclosure, mindfulness, and storytelling. Core components will be fixed across sites; however, there will be an opportunity to contextually specify certain content (e.g., regarding local myths). The intervention will also include the existing Together by St. Jude platform, a comprehensive multilingual online educational platform for pediatric cancer. In addition to general pediatric cancer education, this platform contains material on myth busting, storytelling. and narrative medicine. Existing material and the Together team's support will be used to develop additional stigma-tailored content as needed. The Together platform will be used in the intervention and serve as the education control in Aim 3, due to its wide accessibility in 12 languages.
Patients and clinicians who complete the intervention, will also be asked to complete three validated survey measures. These are the Acceptability of Intervention Measure (AIM), Intervention Appropriateness Measure (IAM), and Feasibility of Intervention Measure (FIM).
Interviews will be done with patients and clinicians involved in Aim 3. Interviews will be individual and will look at the experiences of the intervention and stigma in pediatric cancer.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria, AIM 1:
- Children with cancer who are actively receiving chemotherapy, radiation, and/or surgery or caregivers of children with cancer actively receiving chemotherapy, radiation, and/or surgery
- Ages 8 to 17.9 years (patients); age 18+ (caregivers)
- Speaks Arabic, English, or Spanish (St. Jude will enroll English-speakers only).
Inclusion Criteria, AIM 3:
- Children with cancer who are actively receiving chemotherapy, radiation, and/or surgery or caregivers of children with cancer actively receiving chemotherapy, radiation, and/or surgery
- Ages 8 to 17.9 years (patients); age 18+ (caregivers)
- Speaks Arabic, English, or Spanish (St. Jude will enroll English-speakers only)
- Experienced moderate-high scores in at least 1 domain as assessed by baseline KidsCanSHINE or CaregiversCanSHINE survey assessments.
- Specify any clinical (e.g., life expectancy, co-existing disease demographic (e.g., age) or other characteristics that preclude appropriate diagnosis, treatment or follow-up in the trial.
Tratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- Asignación al azar
- Enmascaramiento
- Sin enmascaramiento
Pediatric Stigma Standard Education and Adapted Stigma Intervention
Aim 3 (See Detailed Description)
Other: Pediatric Stigma Standard Education and Adapted Stigma Intervention
Pediatric Stigma Standard Education
Aim 3 (See Detailed Description)
Other: Pediatric Stigma Education
Pediatric Stigma Education OTHER
See Detailed Description
Pediatric Stigma Standard Education and Adapted Stigma Intervention OTHER
See Detailed Description
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Mean change in patient stigma score from baseline to six months as reported by the KidsCanSHINE tool
Plazo: Baseline and at 6 months (+/- 1 month)
KidsCanSHINE survey tool inquires about the experience of stigma in multiple dimensions and about related patient reported quality of life metrics, information on their diagnosis and treatment course, perceptions of care quality, and demographic information (sex, age, school information, treating institution), This tool uses a 5-point Likert scale and stigma will be assessed across 3 domains. The scale has a range from 1 to 5. Selecting 1 indicates "Almost never" and selecting 5 indicates "Almost always." Higher scores indicate higher levels of stigma.
Mean change in caregiver stigma score from baseline to six months as reported by the CaregiversCanSHINE tool
Plazo: Baseline and at 6 months (+/- 1 month)
The CaregiversCanSHINE survey tool inquires about the experience of stigma in multiple dimensions and about information related to being a caregiver of a child with cancer, including reported quality of life metrics, information on their child's diagnosis and treatment course, perceptions of care quality, and demographic information (sex, age at diagnosis, relationship to the patient, etc). This tool uses a 5-point Likert scale and stigma will be assessed across 3 domains. The scale has a range from 1 to 5. Selecting 1 indicates "Almost never" and selecting 5 indicates "Almost always." Higher scores indicate higher levels of stigma.
Changes in stigma score after intervention as reported by the KidsCanSHINE tool
Plazo: Baseline, Post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The KidsCanSHINE survey tool inquires about the experience of stigma in multiple dimensions. This tool uses a 5-point Likert scale and stigma will be assessed across 3 domains. The scale has a range from 1 to 5. Selecting 1 indicates "Almost never" and selecting 5 indicates "Almost always." Higher scores indicate higher levels of stigma. Individuals will complete the assessments at baseline, immediately after the intervention, and at conclusion of the pilot (six months after intervention).
Changes in stigma score after intervention as reported by the CaregiversCanSHINE tool
Plazo: Baseline, Post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The CaregiversCanSHINE survey tool inquires about the experience of stigma in multiple dimensions. This tool uses a 5-point Likert scale and stigma will be assessed across 3 domains. The scale has a range from 1 to 5. Selecting 1 indicates "Almost never" and selecting 5 indicates "Almost always." Higher scores indicate higher levels of stigma. Individuals will complete the assessment at baseline, immediately after the intervention, and at conclusion of the pilot (six months after intervention).
Characterization of Internalized Stigma as reported by the KidsCanSHINE tool
Plazo: At baseline (as appropriate), post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The KidsCanSHINE survey tool inquiries about the experience of stigma in multiple dimensions, including Internalized Stigma. Each item in this domain is scored on a Likert Scale, from 1 (Almost Never) to 5 (Almost Always). Investigators will evaluate the average Internalized Stigma score as reported by patients.
Characterization of Perceived Stigma as reported by the KidsCanSHINE tool
Plazo: At baseline (as appropriate), post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The KidsCanSHINE survey tool inquiries about the experience of stigma in multiple dimensions, including Perceived Stigma. Each item in this domain is scored on a Likert Scale, from 1 (Almost Never) to 5 (Almost Always). Investigators will evaluate the average Perceived Stigma score as reported by patients.
Characterization of Discrimination Experiences as reported by the KidsCanSHINE tool
Plazo: At baseline (as appropriate), post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The KidsCanSHINE survey tool inquiries about the experience of stigma in multiple dimensions, including Discrimination Experiences. Each item in this domain is scored on a Likert Scale, from 1 (Almost Never) to 5 (Almost Always). Investigators will evaluate the average Discrimination Experiences score as reported by patients.
Characterization of Internalized Stigma as reported by the CaregiversCanSHINE tool
Plazo: At baseline (as appropriate), post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The CaregiversCanSHINE survey tool inquiries about the experience of stigma in multiple dimensions, including Internalized Stigma. Each item in this domain is scored on a Likert Scale, from 1 (Almost Never) to 5 (Almost Always). Investigators will evaluate the average Internalized Stigma score as reported by caregivers.
Characterization of Perceived Stigma as reported by the CaregiversCanSHINE tool
Plazo: At baseline (as appropriate), post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The CaregiversCanSHINE survey tool inquiries about the experience of stigma in multiple dimensions, including Perceived Stigma. Each item in this domain is scored on a Likert Scale, from 1 (Almost Never) to 5 (Almost Always). Investigators will evaluate the average Perceived Stigma score as reported by caregivers.
Characterization of Discrimination Experiences as reported by the CaregiversCanSHINE tool
Plazo: At baseline (as appropriate), post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
The CaregiversCanSHINE survey tool inquiries about the experience of stigma in multiple dimensions, including Discrimination Experiences. Each item in this domain is scored on a Likert Scale, from 1 (Almost Never) to 5 (Almost Always). Investigators will evaluate the average Discrimination Experiences score as reported by caregivers.
Feasibility of Intervention
Plazo: Post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
Participants and clinicians who complete the intervention will be asked to complete the Feasibility of Intervention Measure (FIM). The FIM is used to assess how feasible it is to implement a specific intervention. The FIM measure includes four itemized responses that are scored from one to five (1=Completely disagree, 2=Disagree, 3=Neither agree nor disagree, 4=Agree, 5=Completely agree). Higher scores indicate greater perceived feasibility of the intervention.
Acceptability of Intervention
Plazo: Post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
Participants and clinicians who complete the intervention will be asked to complete the Acceptability of Intervention Measure (AIM). The AIM is a four-item scale used to assess the acceptability of an intervention. It includes four itemized responses that are scored from one to five (1=Completely disagree, 2=Disagree, 3=Neither agree nor disagree, 4=Agree, 5=Completely agree). Higher scores indicating greater acceptability.
Appropriateness of Intervention
Plazo: Post intervention (intervention will last 4-6 weeks), and six months after intervention (+/- 1 month)
Participants and clinicians who complete the intervention will be asked to complete the Appropriateness Measure (IAM). The Intervention Appropriateness Measure (IAM) is a four-item scale used to assess the appropriateness of interventions by capturing individual perspectives on the alignment of the intervention with professional values and perceived efficacy in meeting patient needs. Each item is rated on a 5-point Likert scale (1=Completely disagree, 2=Disagree, 3=Neither agree nor disagree, 4=Agree, 5=Completely agree). A higher score on the IAM indicates a stronger perception that the intervention is appropriate for the given situation and context.
Qualitative Interviews
Plazo: Within 4 weeks of the final component of the intervention
The investigators will conduct a qualitative assessment on experiences of the intervention and stigma in pediatric cancer. Audio recordings of qualitative data will be translated and transcribed into English. Transcripts will be de-identified, segmented, and uploaded to MAXQDA for analysis.
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
St. Jude Children's Research HospitalMemphis, Tennessee, United StatesReclutando
Equipo y fechas
- Patrocinador principal
- St. Jude Children's Research Hospital
- Inicio del estudio
- 2026-12 Estimado
- Finalización primaria
- 2031-12 Estimado
- Finalización del estudio
- 2031-12 Estimado
- Primera publicación
- 20 oct 2026 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
Stigma Healing Inventory Evaluation
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026
